UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 8-K
___________________________
Current Report
Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934☐
Date of Report (Date of earliest event reported): February 24, 2020
___________________________
(Exact name of registrant as specified in its charter)
___________________________
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||
(Address of Principal Executive Offices, including Zip Code)
(888 ) 969-7879
(Registrant’s Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On February 24, 2020, Retrophin, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter and fiscal year ended December 31, 2019. A copy of the press release and accompanying information is attached as Exhibit 99.1 to this current report.
The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02, and Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RETROPHIN, INC. | ||||||||
Dated: February 24, 2020 | By: | /s/ Eric Dube | ||||||
Name: | Eric Dube | |||||||
Title: | Chief Executive Officer | |||||||
Exhibit 99.1
Contact: |
Chris Cline, CFA |
Vice President, Investor Relations & Corporate Communications |
760-260-8600 |
IR@retrophin.com |
Retrophin Reports Fourth Quarter and Full Year 2019 Financial Results
Pivotal DUPLEX and PROTECT studies of sparsentan enrolling towards topline readouts to support potential NDA and CMA filings
Full year 2019 net product sales of $175 million
SAN DIEGO, February 24, 2020 - Retrophin, Inc. (NASDAQ: RTRX) today reported its fourth quarter and full year 2019 financial results and provided a corporate update.
• | The Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) nears enrollment of 190 patients to support the 36-week proteinuria analysis; topline data on-track for first half of 2021 |
• | The Phase 3 PROTECT Study remains in position to reach enrollment of 280 patients with IgA nephropathy (IgAN) by early 2021 and report topline data in the first half of 2022 |
• | Net product sales for the fourth quarter of 2019 were $46.7 million, compared to $43.8 million for the same period in 2018 |
• | Net product sales for the full year 2019 were $175.3 million, compared to $164.2 million for the full year 2018 |
• | Cash, cash equivalents and marketable securities, as of December 31, 2019, totaled $398.5 million |
“In 2019 we strengthened our focus through disciplined decisions to move beyond the clinical programs that did not meet our expectations, and we successfully executed on the key strategies to advance our pivotal studies of sparsentan in FSGS and IgA nephropathy,” said Eric Dube, Ph.D., chief executive officer of Retrophin. “With its potential to become the first medicine approved for FSGS and IgA nephropathy, we are seeing growing enthusiasm for sparsentan among the nephrology community and anticipation for the topline readouts from the 36-week proteinuria assessments in DUPLEX and PROTECT. In 2020 we will continue to focus on completing enrollment and maintaining high quality trial conduct in these two pivotal studies, while simultaneously preparing for regulatory submissions for the programs. Further, we will continue to focus on building upon our existing commercial capabilities in order to support the continued organic growth of our approved products, and ultimately maximizing sparsentan’s potential for patients.”
Fourth Quarter and Full Year 2019 Financial Results
Net product sales for the fourth quarter of 2019 were $46.7 million, compared to $43.8 million for the same period in 2018. For the full year 2019, net product sales were $175.3 million, compared to $164.2 million for the same period in 2018. The increase in net product sales is attributable to growth across the Company’s commercial products including the launch of THIOLA EC®. In 2020, the Company anticipates mid-single-digit percentage growth in net product sales compared to 2019.
Research and development (R&D) expenses for the fourth quarter of 2019 were $36.4 million, compared to $32.0 million for the same period in 2018. For the full year 2019, R&D expenses were $141.0 million, compared to $123.8 million for the same period in 2018. The difference is largely attributable to increased support of clinical and product development efforts. On a non-GAAP adjusted basis, R&D expenses were $34.5 million for the fourth quarter of 2019, compared to $30.1 million for the same period in 2018. For the full year 2019, non-GAAP adjusted R&D expenses were $132.9 million, compared to $116.6 million in 2018.
Selling, general and administrative (SG&A) expenses for the fourth quarter of 2019 were $27.5 million, compared to $26.0 million for the same period in 2018. For the full year 2019, SG&A expenses were $129.0 million, compared to $103.7 million for the same period in 2018. The difference is largely
attributable to increased headcount as a result of the Company’s operational growth, and professional fees. On a non-GAAP adjusted basis, SG&A expenses were $19.6 million for the fourth quarter of 2019, compared to $18.1 million for the same period in 2018. For the full year 2019, non-GAAP adjusted SG&A expenses were $95.5 million, compared to $72.4 million in 2018.
Total other expense, net, for the fourth quarter of 2019 was $2.1 million, compared to $2.5 million for the same period in 2018. For the full year 2019, total other expense, net, was $9.1 million, compared to $21.8 million for the same period in 2018. The difference is largely attributable to a loss on early extinguishment of debt related to the repurchase of outstanding convertible notes due 2019 effected in September 2018.
Net loss for the fourth quarter of 2019 was $30.3 million, or $0.70 per basic share, compared to $7.5 million, or $0.18 per basic share for the same period in 2018. For the full year 2019, net loss was $146.4 million, or $3.46 per basic share, compared to $102.7 million, or $2.54 per basic share for the same period in 2018. On a non-GAAP adjusted basis, net loss for the fourth quarter of 2019 was $11.2 million, or $0.26 per basic share, compared to a net loss of $8.5 million, or $0.21 per basic share for the same period in 2018. For the full year 2019, non-GAAP adjusted net loss was $89.9 million, or $2.12 per basic share, compared to a non-GAAP adjusted net income of $51.8 million, or $1.28 per basic share for the same period in 2018.
As of December 31, 2019, the Company had cash, cash equivalents and marketable securities of $398.5 million.
Program Updates
Sparsentan
• | The Company continues patient enrollment in the pivotal Phase 3 DUPLEX Study, a global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating the safety and efficacy of sparsentan in approximately 300 patients with FSGS. The DUPLEX Study protocol provides for an unblinded analysis of at least 190 patients to be performed after 36 weeks of treatment to evaluate the interim efficacy endpoint - the proportion of patients achieving a FSGS partial remission of proteinuria endpoint (FPRE), which is defined as urine protein-to-creatinine ratio (Up/C) ≤1.5 g/g and a >40 percent reduction in Up/C from baseline, at Week 36. While the confirmatory endpoint of the study is the change in slope of estimated glomerular filtration rate (eGFR) after 108 weeks of treatment, successful achievement of the interim 36-week proteinuria endpoint is expected to serve as the basis for submission of a New Drug Application (NDA) under the Subpart H accelerated approval pathway in the U.S. and Conditional Marketing Authorization (CMA) consideration in Europe. Top-line efficacy data from the 36-week proteinuria endpoint analysis are expected in the first half of 2021. |
• | The PROTECT Study, a global, randomized, multicenter, double-blind, parallel-arm, active-controlled pivotal Phase 3 clinical trial evaluating the safety and efficacy of sparsentan in approximately 280 patients with IgAN, continues to enroll. The primary efficacy endpoint in the PROTECT Study is the change in proteinuria (urine protein-to-creatinine ratio) from baseline after 36 weeks of treatment. Successful achievement of this endpoint is expected to support submission of an NDA under the Subpart H accelerated approval pathway in the U.S., as well as an application for CMA consideration in Europe. Secondary efficacy endpoints include change in eGFR from baseline to four weeks post-cessation of randomized treatment, as well as the rate of change in eGFR over 52-week and 104-week periods following the first six weeks of randomized treatment. Top-line efficacy data from the 36-week proteinuria endpoint analysis are expected in the first half of 2022. |
Chenodal®
• | In January 2020, the Company randomized the first patients in the RESTORE Study, a Phase 3 clinical trial to evaluate the effects of Chenodal® (chenodeoxycholic acid) in approximately 12 patients with cerebrotendinous xanthomatosis (CTX). While Chenodal is not labeled or marketed for CTX, it is currently considered the standard of care. The pivotal study is anticipated to ultimately support an NDA submission for marketing authorization of Chenodal for CTX in the United States. |
Conference Call Information
Retrophin will host a conference call and webcast today, Monday, February 24, 2020 at 4:30 p.m. ET to discuss company updates as well as fourth quarter and full year 2019 financial results. To participate in the conference call, dial +1-855-219-9219 (U.S.) or +1-315-625-6891 (International), confirmation code 3436545 shortly before 4:30 p.m. ET. The webcast can be accessed at retrophin.com, in the Events and Presentations section, and will be archived for at least 30 days. A replay of the call will be available from 7:30 p.m. ET, February 24, 2020 to 7:30 p.m. ET, March 2, 2020. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 3436545.
Use of Non-GAAP Financial Measures
To supplement Retrophin’s financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP adjusted financial measures in this press release and the accompanying tables. The Company believes that these non-GAAP financial measures are helpful in understanding its past financial performance and potential future results. They are not meant to be considered in isolation or as a substitute for comparable GAAP measures, and should be read in conjunction with the consolidated financial statements prepared in accordance with GAAP. Retrophin’s management regularly uses these supplemental non-GAAP financial measures internally to understand, manage
and evaluate its business and make operating decisions. In addition, Retrophin believes that the use of these non-GAAP measures enhances the ability of investors to compare its results from period to period and allows for greater transparency with respect to key financial metrics the Company uses in making operating decisions.
Investors should note that these non-GAAP financial measures are not prepared under any comprehensive set of accounting rules or principles and do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP. Investors should also note that these non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future the Company may exclude other items, or cease to exclude items that it has historically excluded, for purposes of its non-GAAP financial measures; because of the non-standardized definitions, the non-GAAP financial measures as used by the Company in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the Company’s competitors and other companies.
As used in this press release, (i) the historical non-GAAP net income (loss) measures exclude from GAAP net income (loss), as applicable, stock-based compensation expense, amortization and depreciation expense, revaluation of acquisition related contingent consideration and income tax; (ii) the historical non-GAAP SG&A expense measures exclude from GAAP SG&A expenses, as applicable, stock-based compensation expense, and amortization and depreciation expense; (iii) the historical non-GAAP R&D expense measures exclude from GAAP R&D expenses, as applicable, stock-based compensation expense, and depreciation and amortization expense.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam®, Thiola® and Thiola EC®.
Retrophin.com
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, success of its commercial products as well as risks and uncertainties associated with the Company's preclinical and clinical stage pipeline. Specifically, the Company faces risks associated with market acceptance of its commercial products including efficacy, safety, price, reimbursement and benefit over competing therapies. The risks and uncertainties the Company faces with respect to its preclinical and clinical stage pipeline include risk that the Company's clinical candidates will not be found to be safe or effective and that current clinical trials will not proceed as planned. Specifically, the Company faces the risk that the Phase 3 clinical trial of sparsentan in FSGS will not demonstrate that sparsentan is safe or effective or serve as a basis for accelerated approval of sparsentan as planned; risk that the Phase 3 clinical trial of sparsentan in IgAN will not demonstrate that sparsentan is safe or effective or serve as the basis for accelerated approval of sparsentan as planned; and for each of its development programs, risk associated with enrollment of clinical trials for rare diseases and risk that ongoing clinical trials may not proceed on expected timelines or may be delayed for safety, regulatory or other reasons and risk that the product candidates will not be approved for efficacy, safety, regulatory or other reasons. The Company faces risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates; risk relating to the Company's dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties; risks associated with regulatory interactions; and risks and uncertainties relating to competitive products, including potential generic competition with certain of the Company’s products, and technological changes that may limit demand for the Company's products. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in the Company's most recent Form 10-Q, Form 10-K and other filings with the Securities and Exchange Commission.
RETROPHIN, INC. AND SUBSIDIARIES | ||||||||
CONSOLIDATED BALANCE SHEETS | ||||||||
(in thousands, except share amounts) | ||||||||
December 31, 2019 | December 31, 2018 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 62,436 | $ | 102,873 | ||||
Marketable securities | 336,088 | 368,668 | ||||||
Accounts receivable, net | 18,048 | 12,662 | ||||||
Inventory, net | 6,082 | 5,619 | ||||||
Prepaid expenses and other current assets | 5,015 | 4,140 | ||||||
Prepaid taxes | 1,395 | 1,716 | ||||||
Total current assets | 429,064 | 495,678 | ||||||
Property and equipment, net | 2,891 | 3,146 | ||||||
Other assets | 14,709 | 7,709 | ||||||
Investment-equity | — | 15,000 | ||||||
Intangible assets, net | 157,200 | 186,691 | ||||||
Goodwill | 936 | 936 | ||||||
Total assets | $ | 604,800 | $ | 709,160 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 26,614 | $ | 6,954 | ||||
Accrued expenses | 51,745 | 49,695 | ||||||
Other current liabilities | 8,590 | 6,165 | ||||||
Business combination-related contingent consideration | 8,500 | 19,350 | ||||||
Convertible debt | — | 22,457 | ||||||
Total current liabilities | 95,449 | 104,621 | ||||||
Convertible debt | 204,861 | 195,091 | ||||||
Other noncurrent liabilities | 20,894 | 17,545 | ||||||
Business combination-related contingent consideration, less current portion | 62,400 | 73,650 | ||||||
Total liabilities | 383,604 | 390,907 | ||||||
Stockholders' Equity: | ||||||||
Preferred stock $0.0001 par value; 20,000,000 shares authorized; 0 issued and outstanding as of December 31, 2019 and 2018, respectively | — | — | ||||||
Common stock $0.0001 par value; 100,000,000 shares authorized; 43,088,921 and 41,389,524 issued and outstanding as of December 31, 2019 and 2018, respectively | 4 | 4 | ||||||
Additional paid-in capital | 636,910 | 589,795 | ||||||
Accumulated deficit | (416,444 | ) | (270,017 | ) | ||||
Accumulated other comprehensive income (loss) | 726 | (1,529 | ) | |||||
Total stockholders' equity | 221,196 | 318,253 | ||||||
Total liabilities and stockholders' equity | $ | 604,800 | $ | 709,160 | ||||
Note: Certain adjustments / reclassifications have been made to prior periods to conform to current year presentation.
RETROPHIN, INC. AND SUBSIDIARIES | |||||||||||||||
CONSOLIDATED STATEMENT OF OPERATIONS | |||||||||||||||
(in thousands, except share and per share data) | |||||||||||||||
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
(unaudited) | |||||||||||||||
Net product sales: | |||||||||||||||
Tiopronin products | $ | 26,246 | $ | 23,855 | $ | 95,638 | $ | 89,176 | |||||||
Bile acid products | 20,442 | 19,916 | 79,700 | 75,070 | |||||||||||
Total net product sales | 46,688 | 43,771 | 175,338 | 164,246 | |||||||||||
Operating expenses: | |||||||||||||||
Cost of goods sold | 1,725 | 1,603 | 5,234 | 5,527 | |||||||||||
Research and development | 36,366 | 31,995 | 140,963 | 123,757 | |||||||||||
Selling, general and administrative | 27,533 | 25,955 | 128,951 | 103,654 | |||||||||||
Change in fair value of contingent consideration | 9,231 | (10,797 | ) | 15,051 | 11,590 | ||||||||||
Restructuring | — | — | — | (242 | ) | ||||||||||
Impairment of L-UDCA IPR&D intangible asset | — | — | 25,500 | — | |||||||||||
Write off of L-UDCA contingent consideration | — | — | (18,000 | ) | — | ||||||||||
Impairment of long-term investment | — | — | 15,000 | — | |||||||||||
Total operating expenses | 74,855 | 48,756 | 312,699 | 244,286 | |||||||||||
Operating loss | (28,167 | ) | (4,985 | ) | (137,361 | ) | (80,040 | ) | |||||||
Other Income (expense), net: | |||||||||||||||
Other income (expense), net | 359 | (102 | ) | (314 | ) | (474 | ) | ||||||||
Interest income | 2,180 | 2,697 | 10,055 | 5,499 | |||||||||||
Interest expense | (4,599 | ) | (5,065 | ) | (18,828 | ) | (9,810 | ) | |||||||
Loss on extinguishment of debt | — | — | — | (17,042 | ) | ||||||||||
Change in fair value of derivative instruments | — | — | — | — | |||||||||||
Total other expense, net | (2,060 | ) | (2,470 | ) | (9,087 | ) | (21,827 | ) | |||||||
Loss before benefit (provision) for income taxes | (30,227 | ) | (7,455 | ) | (146,448 | ) | (101,867 | ) | |||||||
Income tax provision | (32 | ) | — | 21 | (811 | ) | |||||||||
Net loss | $ | (30,259 | ) | $ | (7,455 | ) | $ | (146,427 | ) | $ | (102,678 | ) | |||
Net earnings (loss) per common share, basic | $ | (0.70 | ) | $ | (0.18 | ) | $ | (3.46 | ) | $ | (2.54 | ) | |||
Net earnings (loss) per common share, diluted | $ | (0.70 | ) | $ | (0.18 | ) | $ | (3.46 | ) | $ | (2.54 | ) | |||
Weighted average common shares outstanding, basic | 43,023,479 | 41,275,872 | 42,339,961 | 40,433,171 | |||||||||||
Weighted average common shares outstanding, diluted | 43,023,479 | 41,275,872 | 42,339,961 | 40,433,171 | |||||||||||
Note: Certain adjustments / reclassifications have been made to prior periods to conform to current year presentation.
RETROPHIN, INC. AND SUBSIDIARIES | |||||||||||||||
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION | |||||||||||||||
(in thousands, except share and per share data) | |||||||||||||||
(unaudited) | |||||||||||||||
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
GAAP operating loss | $ | (28,167 | ) | $ | (4,985 | ) | $ | (137,361 | ) | $ | (80,040 | ) | |||
R&D operating expense | (36,366 | ) | (31,995 | ) | (140,963 | ) | (123,757 | ) | |||||||
Stock compensation | 1,609 | 1,632 | 6,910 | 6,224 | |||||||||||
Amortization & depreciation | 292 | 292 | 1,159 | 976 | |||||||||||
Subtotal non-GAAP items | 1,901 | 1,924 | 8,069 | 7,200 | |||||||||||
Non-GAAP R&D expense | (34,465 | ) | (30,071 | ) | (132,894 | ) | (116,557 | ) | |||||||
SG&A operating expense | (27,533 | ) | (25,955 | ) | (128,951 | ) | (103,654 | ) | |||||||
Stock compensation | 2,888 | 3,222 | 14,195 | 13,550 | |||||||||||
Amortization & depreciation | 4,998 | 4,587 | 19,249 | 17,692 | |||||||||||
Subtotal non-GAAP items | 7,886 | 7,809 | 33,444 | 31,242 | |||||||||||
Non-GAAP SG&A expense | (19,647 | ) | (18,146 | ) | (95,507 | ) | (72,412 | ) | |||||||
Change in fair value of contingent consideration | 9,231 | (10,797 | ) | 15,051 | 11,590 | ||||||||||
Subtotal non-GAAP items | 19,018 | (1,064 | ) | 56,564 | 50,032 | ||||||||||
Non-GAAP operating loss | $ | (9,149 | ) | $ | (6,049 | ) | $ | (80,797 | ) | $ | (30,008 | ) | |||
GAAP net loss | $ | (30,259 | ) | $ | (7,455 | ) | $ | (146,427 | ) | $ | (102,678 | ) | |||
Non-GAAP operating loss adjustments | 19,018 | (1,064 | ) | 56,564 | 50,032 | ||||||||||
Income tax provision | 32 | — | (21 | ) | 811 | ||||||||||
Non-GAAP net loss | $ | (11,209 | ) | $ | (8,519 | ) | $ | (89,884 | ) | $ | (51,835 | ) | |||
Per share data: | |||||||||||||||
Net earnings per common share, basic | $ | (0.26 | ) | $ | (0.21 | ) | $ | (2.12 | ) | $ | (1.28 | ) | |||
Weighted average common shares outstanding, basic | 43,023,479 | 41,275,872 | 42,339,961 | 40,433,171 | |||||||||||
Note: Certain adjustments / reclassifications have been made to prior periods to conform to current year presentation.